dm+d

Unassigned

New Medicines

Moderate to severe atopic dermatitis, inadequately controlled by other therapies

Information

New molecular entity
Galderma
Galderma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A humanised monoclonal antibody targeted against the IL-31 receptor, a cytokine reported to be associated with pruritus in atopic dermatitis [1]
Atopic eczema is common and the prevalence is increasing. Eczema affects 15-20% of school children and 2-10% of adults.
Moderate to severe atopic dermatitis, inadequately controlled by other therapies
Subcutaneous

Moderate to severe prurigo nodularis (PN)

Information

Licence extension / variation
Galderma
Galderma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A humanised monoclonal antibody targeted against the IL-31 receptor, a cytokine reported to be associated with pruritus in atopic dermatitis
The condition appears to be relatively common, particularly among patients who have some of the associated/precipitating conditions (infections, acute kidney injury, psychiatric conditions, malignancies); however, there are no surveys of its prevalence in the general population. It is more common in middle-aged women [1].
Moderate to severe prurigo nodularis (PN)
Subcutaneous injection